Summary
Edwards Lifesciences Corporation (EW) announced on July 15, 2020, a significant addition to its Board of Directors. Paul A. LaViolette has been appointed to the Board, effective July 13, 2020, and will also serve on the Compensation and Governance Committee. This appointment is a key development for the company's governance structure, bringing potentially new perspectives to its strategic and compensation decisions. Mr. LaViolette's appointment appears routine, with no disclosed arrangements with other parties or material interests in company transactions requiring specific disclosure. He will be compensated according to the standard director compensation policy, as outlined in the company's prior filings, and will receive the standard indemnification agreement. Investors should note this as a governance update that could influence future board oversight and strategy.
Key Highlights
- 1Appointment of Paul A. LaViolette to the Board of Directors, effective July 13, 2020.
- 2Mr. LaViolette will also serve as a member of the Compensation and Governance Committee.
- 3No disclosed arrangements or understandings between Mr. LaViolette and any other persons for his selection.
- 4Mr. LaViolette has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
- 5Director will receive standard compensation for non-employee directors.
- 6Company will enter into its standard form of indemnification agreement with Mr. LaViolette.
- 7Announcement accompanied by a press release filed as Exhibit 99.1.